INTRODUCTION
============

Osteoarthritis (OA) is the most common form of degenerative arthritis; it is a widespread, slowly developing disease, with a high prevalence that increases with age \[[@B1][@B2]\]. The most commonly affected large weight-bearing joints are the knees, where the disease is particularly disabling, since it causes difficulty in rising from a chair, climbing stairs, standing and walking \[[@B3]\].

Pain is the main reason for OA patients to seek clinical services \[[@B4]\]. The management of early-stage OA is fundamental for effective symptom relief, management of the resulting functional limitations, and enhancing the health-related quality of life.

The treatment methods for knee OA are diverse. Biomechanical interventions, intra-articular corticosteroids, exercise (land-based and water-based), self-management and education, strength training, weight management, acetaminophen, balneotherapy, capsaicin, mobility aids, duloxetine, oral non-steroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs are recommended in the 2010 Osteoarthritis Research Society International (OARSI) guidelines \[[@B5]\]. However, the results of these treatments are not consistent, and patients with OA continue to experience pain \[[@B4]\]. Therefore, we are interested formulating in new strategies to reduce pain and improve function.

Extracorporeal shock wave therapy (ESWT) was first used to break kidney stones. Its use was proposed for musculoskeletal disorders as the result of an incidental observation of an osteoblastic response pattern, during animal studies, in the late 1980s \[[@B6]\]. In recent years, ESWT has been widely used for pain relief and the treatment of musculoskeletal disorders, such as epicondylitis, plantar fasciitis, calcific tendinitis, and so on \[[@B7][@B8][@B9]\]. The procedure is non-invasive, has a low instance of complication and does not require hospitalization. Veterinarians first began to use ESWT to treat equine knee OA \[[@B10]\]. Several studies found that this procedure showed reduced progression of OA, with decreased articular cartilage degradation and improved motor dysfunction, as well as pain relief in animals with OA \[[@B11][@B12][@B13]\]. In recent years, Zhao et al. \[[@B14]\] have investigated the efficacy of ESWT in human knee OA. They determined that ESWT is effective in reducing pain and improving knee function; however, they did not establish a treatment protocol for ESWT, regarding the proper amount of energy.

The purpose of this study was, therefore to investigate the dose-related effects of ESWT (at different total energy flux density \[EFD\]) in patients with knee OA.

MATERIALS AND METHODS
=====================

Subjects
--------

All patients who had unilateral knee pain, from January 2013 to December 2013, were recruited. The inclusion criteria of the subjects were 1) aged \>45; 2) diagnosed as symptomatic knee OA for at least 3 months, according to the clinical criteria of the American College of Rheumatology \[[@B15]\]; 3) their radiographic findings had to be compatible with knee OA, with a Kellgren-Lawrence (K-L) grade II or III in a simple X-ray \[[@B16]\]; and 4) had tenderness on medial tibial plateau area.

We excluded patients who had comorbidities, such as any neurologic disorders or systemic disease, previous surgical intervention or intra-articular injection in the last 6 months, any contraindication to magnetic resonance imaging or radiography, or trauma history on knee.

Seventy-five subjects were recruited, 60 of which met the inclusion criteria. Written informed consent was obtained from all subjects prior to the study. The study was performed in accordance with the principles set forth in the Declaration of Helsinki.

Methods
-------

### Extracorporeal shock wave therapy

We used block randomization via a computerized program. An independent researcher assigned the study subjects to either the low-energy group (group L: n=30, 1,000 shocks/session, EFD per shock 0.040 mJ/mm^2^) or the medium-energy group (group M: n=30, 1,000 shocks/ session, EFD per shock 0.093 mJ/mm^2^), but was not involved in the treatment or the outcome assessment. All subjects received three sessions of ESWT, at once-weekly intervals, at different energy level according to their groups ([Fig. 1](#F1){ref-type="fig"}).

We used the Dornier Epos Ultra (Dornier MedTech, Kennesaw, GA, USA), which was approved in 2001. Our ESWT has an electromagnetic source, and the type of ESWT is the smart focus type. The ESWT was executed by physician who was not involved in the selection and assessment of the patients. At each treatment session, all subjects were positioned in a supine manner, with the affected knee flexed at 90°. The shockwave probe was held stationary on a tender area around the medial tibial plateau. To reduce the loss of shockwave energy at the interface, an aqueous gel was applied between the probe and the skin. The practitioner frequently checked the treatment areas of the patients during the therapy and excluded those who developed side effects on the treatment area, such as bruising or edema. During the course of the experiment, all subjects were prevented from receiving any additional treatment, such as physical therapy, steroid injection, or anti-inflammatory drugs. No bed rest was required after treatment, but a low level of physical activity was recommended for the following 48 hours.

### Outcome measures

The clinical assessments included an assessment of pain, on movement, and a physical function assessment. The primary outcome measure was \'pain on movement\', which was measured using a visual analogue scale (VAS) \[[@B17]\], with 0 indicating no pain and 10 indicating maximum pain. The VAS scores were measured in relation to the degree of pain that patients experienced during their usual daily activity. The secondary outcome measure was \'disability\' on the Roles and Maudsley (RM) score, the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and the Lequesne index. All assessments were performed at the baseline and at 1, 4, and 12 weeks after ESWT by a physician who was not involved in the selection and treatment of patients.

The RM score was used to assess functional evaluation \[[@B18]\]. It was recorded using four categories, based on the pain and activity ranges in daily life: excellent, good, fair, and poor ([Table 1](#T1){ref-type="table"}).

The WOMAC assesses the symptoms of OA and is a validated disease-specific self-reporting questionnaire that refers to the 48 hours before assessment \[19\]. The index consists of five questions covering the severity of the knee pain two questions covering stiffness and 17 questions covering limitations in physical function. The WOMAC score ranges from 0 (best) to 96 (worst), with high score representing worse symptom severity.

The disability of patients with knee OA was assessed using the Lequesne index. The questionnaire included 11 questions regarding knee discomfort, endurance of ambulation, and difficulties in daily life \[[@B20]\]. A maximum score of 26 indicated the greatest degree of dysfunction, and a score of 1-3 indicated a mild dysfunction. A score of less than 7 points indicated an acceptable functional status.

### Statistical analysis

A Student t-test was used to compare the homogeneity of the baseline characteristics between two groups. The treatment effects (over time) within each group and the differences in the treatment effects between the two groups were examined using repeated measure ANOVA. All analyses were performed with the SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA). A p-value of \<0.05 was considered statistically significant.

RESULTS
=======

Patient characteristics
-----------------------

Within the group of 60 patients, 53 were male and 7 were female. Their average age was 64.3±5.8 years old, their average height was 167.8±8.5 cm, and their average weight was 69.4±6.1 kg. The average body mass index (BMI) was 24.0±1.8 kg/m^2^ and the average disease duration was 18.0±4.9 months. The average VAS, RM, and WOMAC scores were 6.02±1.15 points, 3.25±0.75 points, and 57.27±10.75 points, respectively. The average Lequesne index was 14.7±3.3.

There were no significant differences in sex, age, height, weight, BMI, disease duration, VAS score, RM score, WOMAC score, or Lequesne index between the two groups prior to the treatments ([Table 2](#T2){ref-type="table"}). There were no cases in which the treatment was discontinued due to the occurrence of side effects or complications, although some patients complained of minor discomforts like transient skin reddening or swelling.

Changes in pain after the ESWT
------------------------------

At the baseline, the VAS scores in group M and group L were 6.10±1.26 and 5.93±1.15, respectively. After 1 week, the VAS scores in each group were 5.13±0.82 and 4.67±0.48. After 4 weeks, were 2.73±0.83 and 2.77±0.57, and after 12 weeks, they were 1.57±0.50 and 1.90±0.71, respectively. Compared to the baseline, the VAS score significantly decreased with time, up to the 12-week followup for both groups (p\<0.001 for time effect, p\<0.001 for group-time interaction). There were also significant differences between the two groups at 1 week and 12 weeks (p\<0.05) ([Fig. 2](#F2){ref-type="fig"}).

Changes in function after the ESWT
----------------------------------

At the baseline, the RM scores in the two groups were 3.23±0.73 and 3.27±0.76, respectively. After 1 week, the RM scores in the two groups were 2.00±0.53 and 2.43±0.57, respectively. After 4 weeks, they were 1.43±0.50 and 1.73±0.64, and after 12 weeks, they were 1.10±0.31 and 1.23±0.43, respectively. Compared to the baseline, the RM score significantly decreased with time, up to the 12-week follow-up, in both groups (p\<0.001 for time effect, p\<0.05 for group-time interaction); there were significant differences between the two groups at 1 week and 4 weeks (p\<0.05) ([Fig. 3](#F3){ref-type="fig"}).

The WOMAC scores for the two groups were 57.63± 10.21 and 56.90±11.44 at baseline, respectively. After 1 week, WOMAC scores for the two groups were 49.10±12.23 and 49.17±9.77, respectively. After 4 weeks, they were 31.57±9.07 and 39.27±7.15, after 12 weeks, they were 23.20±7.78 and 33.33±7.03, respectively. Compared to the baseline, the WOMAC score significantly decreased with time, up to the 12-week follow-up, in both groups (p\<0.001 for time effect, p\<0.001 for group-time interaction). There were significant differences between the two groups at 4 weeks and 12 weeks (p\<0.05) ([Fig. 4](#F4){ref-type="fig"}).

The Lequesne indices for the two groups were 14.9±3.1 and 14.5±3.5, respectively, at the baseline. After 1 week, they were 13.3±2.8 and 13.6±2.9, respectively; after 4 weeks, they were 8.5±3.3 and 9.7±2.5, and after 12 weeks they were 4.8±1.5 and 7.5±2.2, respectively. Compared to the baseline, the Lequesne index significantly decreased, with time, up to the 12 week follow-up in both groups (p\<0.001 for time effect, p\<0.001 for group-time interaction). There were significant differences between the two groups at 12 weeks (p\<0.05) ([Fig. 5](#F5){ref-type="fig"}).

DISCUSSION
==========

The nonsurgical management of knee OA is essential for effective symptom relief and the management of functional limitations \[[@B21]\]. In January 2010, the OARSI published an update to their recommendations for the treatment of knee OA \[[@B5]\]. In recent years, ESWT has been the leading therapeutic choice for chronic tendinopathy, nonunion of a long bone fracture, and the early stage of avascular necrosis of the femoral head \[[@B6]\]. More recently, the use of ESWT has expanded to include the treatment of OA in animals, and has shown improved motor function and pain management \[[@B11][@B12][@B13]\]. Some studies have shown the efficacy of ESWT for knee OA patients, by reducing pain and improving knee function \[[@B14]\].

We considered that ESWT could have a beneficial effect for the pain and physical function in patients with knee OA. However, the exact mechanisms of ESWT, on knee OA, are complex and have not been clearly explained. The mechanism of ESWT causes selective dysfunction of sensory unmyelinated nerve fibers \[[@B22]\]. It is known to improve the symptoms of OA via an inflammatory response triggered by the secretion of growth factors, and also to repair damaged tissues by encouraging angiogenesis \[[@B23][@B24][@B25]\]. The levels of neuropeptide calcitonin gene-related peptides were decreased in the dorsal root ganglion in a rat OA knee model, after the ESWT treatment; this peptide is expressed by nociceptors and is thought to play a role in the sensation of joint pain \[[@B12]\]. ESWT could reduce the progression of OA in animal models \[[@B13][@B26][@B27]\]. The application of ESWT, for a damaged anterior cruciate ligament in rats, improved subchondral bone remodeling and decreased cartilage degradation \[[@B26]\]. Moreover, the application of ESWT reduced the progression of OA in rabbits, which may be related to the decreased levels of nitric oxide, and is likely mediated by a reduced chondrocyte apoptosis \[[@B13]\].

The ESWT can be divided into different energy influx levels. Some previous studies have divided the ESWT treatment intensity into three levels, which are 1) low intensity (EFD, \<0.08 mJ/mm^2^); 2) medium intensity (EFD, 0.08-0.28 mJ/mm^2^); and 3) high intensity (EFD, \>0.28 mJ/mm^2^) \[[@B28][@B29]\].

While some studies that advocate the use of high intensity energy report that it requires only a single treatment, and that the treatment effects are superior \[[@B30]\], the increased energy influx results in a corresponding increase in pain, local swelling, and tenderness. Therefore, higher intensity treatments usually require local anesthesia, which is known to reduce the efficacy of the treatment \[[@B31]\]. Some basic scientific studies have shown that the ESWT application, for OA, is safe with proper dosing \[[@B32]\]. EFD, applied at \>0.50 mJ/mm^2^, caused degenerative changes in the hyaline cartilage of rats \[[@B33]\]. In addition, by using lower energy, it is possible to prevent patients from having to adapt (quite as much) to the treatment, and also to prevent patients from giving up on their treatment outright as a result of the pain caused by treatments using high energy.

In our study, the treatment effects in the two groups were compared: group L had low energy (0.040 mJ/mm^2^) and group M had medium energy (0.093 mJ/mm^2^), which was applied over three sessions. Our results show that each group improved significantly by the 12-week followup, in terms of the pain and functional scores, compared to the baseline scores. The medium energy group showed a better pain score than the low energy group at 1 week and 12 weeks, a better RM score at 1 week and 4 weeks, a better WOMAC score at 4 weeks and 12 weeks, and a better Lequesne index at 12 weeks. This concurs with the results of previous studies, which demonstrated that higher intensity energy destroys more unmyelinated sensory nerve fibers, and thereby has a greater pain-reducing effect \[[@B22][@B34]\]. The histological reaction to the ESWT is known to be dose-dependent on the total energy, so medium energy group shows greater improvement \[[@B35][@B36]\].

This study has several limitations. For example, the control group was not employed to exclude the placebo effect. The number of patients was relatively small, and the evaluation period (at 12 weeks) was too short to assess fully the long-term effectiveness. An explanation on the principles and mechanisms of the effectiveness of the ESWT are provided in the inferences from past studies. Further studies will be needed to confirm these findings.

In conclusion, the adaptation of the medium energy ESWT was more efficient, in terms of relieving pain and restoring functional outcome, than the low energy ESWT. Therefore, EFD can be considered a significant influencing factor, when treating knee OA with ESWT.
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![A flow diagram, showing the treatment process and assessment. ESWT, extracorporeal shock wave therapy; EFD, energy flux density.](arm-39-616-g001){#F1}

![The visual analogue scale (VAS) score at the baseline and 1-, 4-, and 12-week follow-ups after the extracorporeal shock wave therapy in both groups. This figure shows significant improvement for both groups, in the VAS score, for entire period (^\*\*\*^p\<0.001 for time effect, ^\*\*\*^p\<0.001 for group-time interaction) and significant differences between the two groups at 1 week and 12 weeks (^\*^p\<0.05). Group M, medium-energy (0.093 mJ/mm^2^) group; group L, low-energy (0.040 mJ/mm^2^) group.](arm-39-616-g002){#F2}

![The Roles and Maudsley score at the baseline and 1-, 4-, 12-week follow-ups after the extracorporeal shock wave therapy, in both groups. This figure shows significant improvement for both group in the Roles and Maudsley score over the entire period (^\*\*\*^p\<0.001 for time effect, ^\*\*\*^p\<0.05 for group-time interaction) and significant differences between the two groups at 1 week and 4 weeks (^\*^p\<0.05). Group M, medium-energy (0.093 mJ/mm^2^) group; group L, low-energy (0.040 mJ/mm^2^) group.](arm-39-616-g003){#F3}

![The Western Ontario and McMaster University Osteoarthritis Index (WOMAC) score at the baseline and 1-, 4-, 12-week follow-ups after the extracorporeal shock wave therapy, in both groups. This figure shows significant improvement, for both groups, in WOMAC score over the entire period (^\*\*\*^p\<0.001 for time effect, ^\*\*\*^p\<0.001 for group-time interaction), and significant differences between the two groups at 4 weeks and 12 weeks (^\*^p\<0.05). Group M, medium-energy (0.093 mJ/ mm^2^) group; group L: low-energy (0.040 mJ/mm^2^) group.](arm-39-616-g004){#F4}

![The Lequesne index at the baseline and 1-, 4-, 12- week follow-ups after extracorporeal shock wave therapy, for both groups. This figure shows significant improvement, for both groups, in the Lequesne index over entire period (^\*\*\*^p\<0.001 for time effect, ^\*\*\*^p\<0.001 for grouptime interaction), and significant differences between the two groups at 12 weeks (^\*^p\<0.05). Group M, mediumenergy (0.093 mJ/mm^2^) group; group L: low-energy (0.040 mJ/mm^2^) group.](arm-39-616-g005){#F5}

###### The Roles and Maudsley score
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###### The demographic and baseline clinical characteristics of patients
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Values are presented as number or mean±standard deviation.

Group L, low-energy (0.040 mJ/mm^2^) group; group M, medium-energy (0.093 mJ/mm^2^) group; BMI, body mass index; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster University Osteoarthritis Index.

^a)^Student t-test.
